Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact.


Journal

Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802

Informations de publication

Date de publication:
14 Jul 2020
Historique:
received: 26 06 2019
accepted: 04 07 2020
entrez: 16 7 2020
pubmed: 16 7 2020
medline: 3 3 2021
Statut: epublish

Résumé

Population-wide interventions using malaria testing and treatment might decrease the reservoir of Plasmodium falciparum infection and accelerate towards elimination. Questions remain about their effectiveness and evidence from different transmission settings is needed. A pilot quasi-experimental study to evaluate a package of population-wide test and treat interventions was conducted in six health facility catchment areas (HFCA) in the districts of Kanel, Linguère, and Ranérou (Senegal). Seven adjacent HFCAs were selected as comparison. Villages within the intervention HFCAs were stratified according to the 2013 incidences of passively detected malaria cases, and those with an incidence ≥ 15 cases/1000/year were targeted for a mass test and treat (MTAT) in September 2014. All households were visited, all consenting individuals were tested with a rapid diagnostic test (RDT), and, if positive, treated with dihydroartemisinin-piperaquine. This was followed by weekly screening, testing and treatment of fever cases (PECADOM++) until the end of the transmission season in January 2015. Villages with lower incidence received only PECADOM++ or case investigation. To evaluate the impact of the interventions over that transmission season, the incidence of passively detected, RDT-confirmed malaria cases was compared between the intervention and comparison groups with a difference-in-difference analysis using negative binomial regression with random effects on HFCA. During MTAT, 89% (2225/2503) of households were visited and 86% (18,992/22,170) of individuals were tested, for a combined 77% effective coverage. Among those tested, 291 (1.5%) were RDT positive (range 0-10.8 by village), of whom 82% were < 20 years old and 70% were afebrile. During the PECADOM++ 40,002 visits were conducted to find 2784 individuals reporting fever, with an RDT positivity of 6.5% (170/2612). The combination of interventions resulted in an estimated 38% larger decrease in malaria case incidence in the intervention compared to the comparison group (adjusted incidence risk ratio = 0.62, 95% CI 0.45-0.84, p = 0.002). The cost of the MTAT was $14.3 per person. It was operationally feasible to conduct MTAT and PECADOM++ with high coverage, although PECADOM++ was not an efficient strategy to complement MTAT. The modest impact of the intervention package suggests a need for alternative or complementary strategies.

Sections du résumé

BACKGROUND BACKGROUND
Population-wide interventions using malaria testing and treatment might decrease the reservoir of Plasmodium falciparum infection and accelerate towards elimination. Questions remain about their effectiveness and evidence from different transmission settings is needed.
METHODS METHODS
A pilot quasi-experimental study to evaluate a package of population-wide test and treat interventions was conducted in six health facility catchment areas (HFCA) in the districts of Kanel, Linguère, and Ranérou (Senegal). Seven adjacent HFCAs were selected as comparison. Villages within the intervention HFCAs were stratified according to the 2013 incidences of passively detected malaria cases, and those with an incidence ≥ 15 cases/1000/year were targeted for a mass test and treat (MTAT) in September 2014. All households were visited, all consenting individuals were tested with a rapid diagnostic test (RDT), and, if positive, treated with dihydroartemisinin-piperaquine. This was followed by weekly screening, testing and treatment of fever cases (PECADOM++) until the end of the transmission season in January 2015. Villages with lower incidence received only PECADOM++ or case investigation. To evaluate the impact of the interventions over that transmission season, the incidence of passively detected, RDT-confirmed malaria cases was compared between the intervention and comparison groups with a difference-in-difference analysis using negative binomial regression with random effects on HFCA.
RESULTS RESULTS
During MTAT, 89% (2225/2503) of households were visited and 86% (18,992/22,170) of individuals were tested, for a combined 77% effective coverage. Among those tested, 291 (1.5%) were RDT positive (range 0-10.8 by village), of whom 82% were < 20 years old and 70% were afebrile. During the PECADOM++ 40,002 visits were conducted to find 2784 individuals reporting fever, with an RDT positivity of 6.5% (170/2612). The combination of interventions resulted in an estimated 38% larger decrease in malaria case incidence in the intervention compared to the comparison group (adjusted incidence risk ratio = 0.62, 95% CI 0.45-0.84, p = 0.002). The cost of the MTAT was $14.3 per person.
CONCLUSIONS CONCLUSIONS
It was operationally feasible to conduct MTAT and PECADOM++ with high coverage, although PECADOM++ was not an efficient strategy to complement MTAT. The modest impact of the intervention package suggests a need for alternative or complementary strategies.

Identifiants

pubmed: 32664939
doi: 10.1186/s12936-020-03313-6
pii: 10.1186/s12936-020-03313-6
pmc: PMC7362450
doi:

Substances chimiques

Antimalarials 0
Artemisinins 0
Quinolines 0
artenimol 6A9O50735X
piperaquine A0HV2Q956Y

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

252

Subventions

Organisme : Bill & Melinda Gates Foundation
ID : OPP1148921
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Am J Trop Med Hyg. 1994 Aug;51(2):123-37
pubmed: 8074247
Malar J. 2016 Aug 11;15(1):408
pubmed: 27515533
Parasit Vectors. 2012 Apr 04;5:69
pubmed: 22475528
Lancet. 2010 Nov 6;376(9752):1566-78
pubmed: 21035842
J Clin Microbiol. 2011 Nov;49(11):3885-91
pubmed: 21880972
PLoS One. 2011;6(5):e20179
pubmed: 21629651
Am J Trop Med Hyg. 2015 May;92(5):913-921
pubmed: 25802434
Clin Infect Dis. 2017 May 1;64(9):1221-1227
pubmed: 28369268
Malar J. 2011 Nov 03;10:337
pubmed: 22050911
Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents
pubmed: 19136431
Nat Commun. 2012;3:1237
pubmed: 23212366
Malar J. 2013 Feb 27;12:79
pubmed: 23442748
J Infect Dis. 2015 May 1;211(9):1476-83
pubmed: 25429102
Trop Med Int Health. 2015 Nov;20(11):1438-1446
pubmed: 26171642
Lancet. 2016 Apr 23;387(10029):1775-84
pubmed: 27116283
Malar J. 2011 Apr 13;10:86
pubmed: 21489278
PLoS One. 2012;7(2):e31743
pubmed: 22363717

Auteurs

Ruben O Conner (RO)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Yakou Dieye (Y)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Michael Hainsworth (M)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Adama Tall (A)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Badara Cissé (B)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Farba Faye (F)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Mame Demba Sy (MD)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Amadou Ba (A)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Doudou Sene (D)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Souleymane Ba (S)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Elhadji Doucouré (E)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Tidiane Thiam (T)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Moussa Diop (M)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Kammerle Schneider (K)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Moustapha Cissé (M)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Mady Ba (M)

Programme National de Lutte contre le Paludisme (PNLP), Ministère de la Santé et l'Action Sociale, Dakar, Senegal.

Duncan Earle (D)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Philippe Guinot (P)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Richard W Steketee (RW)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA.

Caterina Guinovart (C)

PATH Malaria Control and Elimination Partnership in Africa (MACEPA), 2201 Westlake Avenue, Suite 200, Seattle, WA, 98121, USA. cguinovart@path.org.
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Rosselló 132, 08036, Barcelona, Spain. cguinovart@path.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH